StockData
Scribe Therapeutics, Inc. logo

Scribe Therapeutics, Inc. (SCTX) shareholders

SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.36−0.63 (-3.71%)

Close on Nov 13, 2026Market cap $309.72MP/E –Yield –

Ownership

Who owns Scribe Therapeutics's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
9 buys · 0 sales
Net bought $71.34M

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Aghazadeh Behzad
Joint filing with Avoro Capital Advisors LLC (13.78%)
3,088,88816.37%13D (active)Jul 24, 2026
RA Capital Management, L.P.
Joint filing with Peter Kolchinsky (9.60%), Rajeev Shah (9.60%) and 1 more
1,802,1789.60%13G (passive)Jul 27, 2026
ELI LILLY & Co1,388,1617.30%13D (active)Jul 23, 2026
Orbimed Advisors LLC
Joint filing with Orbimed Capital Gp Viii LLC (7.20%)
1,348,8257.20%13D (active)Jul 27, 2026

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

FundShares% of SCTXValue% of fundAs of
ARK Genomic Revolution ETF352,0971.86%$6.86M0.44%Jul 31, 2026
Franklin Biotechnology Discovery Fund135,5670.72%$2.64M0.23%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Benjamin L. OakesPresident, CEO, Director506,6022.68%Jul 27, 2026
David ParrotChief Financial Officer2,6660.01%Jul 27, 2026
Svetlana LucasChief Business Officer33,6950.18%Jul 27, 2026
Carl L. GordonDirector348,8251.84%Jul 29, 2026
Advisors Llc OrbimedDirector348,8251.84%Jul 29, 2026
Capital GP VIII LLC OrbiMedDirector––Jul 29, 2026
Behzad AghazadehDirector, 10% owner––Jul 28, 2026
Capital Advisors LLC AvoroDirector, 10% owner––Jul 28, 2026
Ventures LLC AvoroDirector3,088,88816.32%Jul 28, 2026
Joshua BleharskiDirector––Jul 27, 2026
James Dean WatsonDirector––Jul 27, 2026
Benjamin A. Horowitz10% owner––Jul 29, 2026
AH Equity Partners Bio III, L.L.C.10% owner––Jul 29, 2026
Marc L. Andreessen10% owner––Jul 29, 2026
Jennifer A. Doudna10% owner603,5473.19%Jul 29, 2026
AH Bio Fund II, L.P.10% owner––Jul 29, 2026
AH Equity Partners Bio II, L.L.C.10% owner2,749,39214.52%Jul 29, 2026
AH Bio Fund III, L.P.10% owner––Jul 29, 2026
Brett Staahl10% owner524,3362.77%Jul 28, 2026
LILLY & Co ELI10% owner1,054,8285.57%Jul 23, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Ventures LLC Avoro
Director
Jul 28, 2026Buy+7,905$18.25$144.27K3,088,888
AH Equity Partners Bio II, L.L.C.
10% owner
Jul 27, 2026Conversion+2,051,742––2,051,742
AH Equity Partners Bio II, L.L.C.
10% owner
Jul 27, 2026Conversion+697,650––697,650
AH Equity Partners Bio II, L.L.C.
10% owner
Jul 27, 2026Buy+333,333$15.00$5.00M2,385,075
Carl L. Gordon
Director
Jul 27, 2026Conversion+348,825––348,825
Carl L. Gordon
Director
Jul 27, 2026Buy+1,000,000$15.00$15.00M1,348,825
Jennifer A. Doudna
10% owner
Jul 27, 2026Conversion+12,511––603,547
Advisors Llc Orbimed
Director
Jul 27, 2026Conversion+348,825––348,825
Advisors Llc Orbimed
Director
Jul 27, 2026Buy+1,000,000$15.00$15.00M1,348,825
Ventures LLC Avoro
Director
Jul 24, 2026Buy+2,333,333$15.00$35.00M3,030,983
Ventures LLC Avoro
Director
Jul 24, 2026Buy+50,000$22.31$1.12M3,080,983
David Parrot
Chief Financial Officer
Jul 23, 2026Buy+1,333$15.00$20.00K1,333
David Parrot
Chief Financial Officer
Jul 23, 2026Buy+1,333$15.00$20.00K1,333
Svetlana Lucas
Chief Business Officer
Jul 23, 2026Buy+3,000$15.00$45.00K3,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
20.05%
2M shares short
Days to cover
4.0
At 0M shares a day
Change since last report
+49.5%
From 1M shares
Short volume, 20 days
78.2%
Of volume reported to FINRA

Shares sold short, last 4 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Scribe Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 92,177 shares on Sep 21, 2026 over the last 90 days.

See a number that looks wrong?